加载中
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
收盘时
US$2.77
+US$0.015 · +0.54%
盘后
US$2.77
US$0.00 · 0.00%
10月12日 16:10 ET
盘中时间采用ET。市场数据可能有所延迟。
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
日内区间
当前US$2.77
52周区间
当前US$2.77
盘中时间采用ET。市场数据可能有所延迟。
Protara Therapeutics, Inc. is a biotechnology company actively involved in clinical research and development, striving to identify and advance groundbreaking therapies. Their core mission is to tackle significant medical challenges in both oncology and rare disease domains. The company's leading therapeutic candidate, TARA-002, is an investigational cellular therapy currently under evaluation for the treatment of lymphatic malformations. Furthermore, Protara is developing intravenous choline chloride, a potential phospholipid substrate replacement therapy aimed at addressing liver disease associated with intestinal failure. The organization, which was formerly known as ArTara Therapeutics, Inc., underwent a name change to Protara Therapeutics, Inc. in May 2020. Its principal operations are based in New York, New York.
日内区间
当前US$2.77
52周区间
当前US$2.77
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | 36.2万 USD | — | 34.1万 USD | — | — |
| 毛利 | −36.2万 USD | — | −34.1万 USD | — | — |
| 研究与开发 | 4263.3万 USD | 3170.4万 USD | 2478.5万 USD | 1680.8万 USD | 2108.8万 USD |
| 销售、一般及管理费用 | 2191.6万 USD | 1745万 USD | 1862.4万 USD | 2073.7万 USD | 2640.1万 USD |
| 营业费用 | 6418.7万 USD | 4915.4万 USD | 4327.2万 USD | 6706.2万 USD | 4748.9万 USD |
| 利息收入 | 633.1万 USD | 413.5万 USD | 272.7万 USD | 111万 USD | 23.7万 USD |
| 利息支出 | — | — | — | 113.7万 USD | 173.7万 USD |
| 折旧和摊销 | 36.2万 USD | 33.2万 USD | 34.1万 USD | 24.8万 USD | 11.7万 USD |
| 营业利润 | −6454.9万 USD | −4915.4万 USD | −4361.3万 USD | −6706.2万 USD | −4748.9万 USD |
| 净利润 | −5743.9万 USD | −4459.6万 USD | −4042万 USD | −6595.2万 USD | −4725.2万 USD |
公司数据更新于 2026年10月12日。
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$12.00
上涨空间 333.21%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2020年1月10日 | 1:40 | — | — |
已生效 2020年1月10日
1:40
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI639.94万0.00%2.3万亿 USD0.03%US$381.57-0.10%
iShares Russell 2000 ETFIWM380.96万0.00%787.4亿 USD0.19%US$277.9-0.37%
Vanguard Extended Market ETFVXF226.57万0.00%954亿 USD0.05%US$233.52-0.63%
Vanguard Russell 2000 ETFVTWO115.78万0.01%180亿 USD0.06%US$112.27-0.35%
Dimensional - US Small Cap ETFDFAS91.98万0.00%338.69亿 USD0.31%US$78.17-0.23%
Vanguard U.S. Momentum Factor ETFVFMO54.24万0.03%19亿 USD0.13%US$227.71-1.04%
iShares Micro-Cap ETFIWC46.04万0.03%13.17亿 USD0.60%US$181.66-0.73%
U.S. Micro Cap Portfolio ETFDFMC41.16万0.01%75.58亿 USD0.43%US$57.70-0.20%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFVanguard Russell 2000 ETFVTWODimensional - US Small Cap ETFDFASVanguard U.S. Momentum Factor ETFVFMOiShares Micro-Cap ETFIWCU.S. Micro Cap Portfolio ETFDFMCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
